{"id":963720,"date":"2026-05-15T16:19:56","date_gmt":"2026-05-15T20:19:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/"},"modified":"2026-05-15T16:19:56","modified_gmt":"2026-05-15T20:19:56","slug":"biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/","title":{"rendered":"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026"},"content":{"rendered":"
\n

\n MAINZ, Germany,\u00a0May 15, 2026 (GLOBE NEWSWIRE)<\/b> —\u00a0BioNTech SE<\/a> (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) held its Annual General Meeting (\u201cAGM\u201d) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today\u2019s AGM were approved by a majority of the shareholders.<\/p>\n

BioNTech is strengthening its focus on the Company\u2019s growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company’s shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris L\u00f6w-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board. <\/p>\n

Iris L\u00f6w-Friedrich has many years of expertise in the field of clinical development and broad experience in the scientific and medical fields. She also possesses knowledge in the areas of sales and commercialization, management, innovation, and international markets relevant to the Company.
She is an experienced Supervisory Board member and adjunct professor of internal medicine at the faculty of medicine at Goethe University in Frankfurt am Main, Germany. <\/p>\n

Susanne Schaffert is a member of supervisory boards in the healthcare sector, including that of Merck KGaA. She possesses particular expertise in the field of oncology as well as in sales and commercialization with a focus on product launches. Her knowledge spans innovation, research and development, and organizational leadership and management.<\/p>\n

Additionally, shareholders approved the extension of the mandates of BioNTech\u2019s Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, Ph.D., and Prof. Rudolf Staudigl, Ph.D.<\/p>\n

At a meeting held following the AGM, the Supervisory Board elected Helmut Jeggle as its Chairman.<\/p>\n

The voting results for all agenda items can be viewed on the\u00a0Annual General Meeting 2026<\/a>\u00a0website under the section \u2018Voting Results\u2019. The speeches by Chief Executive Officer Prof. Ugur Sahin, M.D., Chief Financial Officer Ram\u00f3n Zapata and the slides presented at the AGM 2026 can be found in section \u2018Speeches and Presentations\u2019 under the same link.<\/p>\n

\n About BioNTech
<\/b>BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.<\/p>\n

For more information, please visit\u00a0www.BioNTech.com<\/a>.<\/p>\n

\n BioNTech Forward-Looking Statements<\/b>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the potential benefits of appointed Supervisory Board members. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.<\/p>\n

The forward-looking statements in this press release are based on BioNTech\u2019s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech\u2019s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements.<\/p>\n

You should review the risks and uncertainties described under the heading \u201cRisk Factors\u201d in BioNTech\u2019s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC\u2019s website at\u00a0www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.\u00a0<\/p>\n

\n CONTACTS<\/b>\n <\/p>\n

\n Investor Relations<\/b>
\n
Douglas Maffei, PhD
Investors@biontech.de<\/a><\/p>\n

\n Media Relations<\/b>
\n
Jasmina Alatovic
Media@biontech.de<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MAINZ, Germany,\u00a0May 15, 2026 (GLOBE NEWSWIRE) —\u00a0BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) held its Annual General Meeting (\u201cAGM\u201d) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today\u2019s AGM were approved by a majority of the shareholders. BioNTech is strengthening its focus on the Company\u2019s growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company’s shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris L\u00f6w-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board. Iris L\u00f6w-Friedrich … <\/p>\n

Continue reading “BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963720","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MAINZ, Germany,\u00a0May 15, 2026 (GLOBE NEWSWIRE) —\u00a0BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) held its Annual General Meeting (\u201cAGM\u201d) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today\u2019s AGM were approved by a majority of the shareholders. BioNTech is strengthening its focus on the Company\u2019s growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company’s shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris L\u00f6w-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board. Iris L\u00f6w-Friedrich … Continue reading "BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T20:19:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026\",\"datePublished\":\"2026-05-15T20:19:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/\"},\"wordCount\":741,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/\",\"name\":\"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==\",\"datePublished\":\"2026-05-15T20:19:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - Market Newsdesk","og_description":"MAINZ, Germany,\u00a0May 15, 2026 (GLOBE NEWSWIRE) —\u00a0BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) held its Annual General Meeting (\u201cAGM\u201d) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today\u2019s AGM were approved by a majority of the shareholders. BioNTech is strengthening its focus on the Company\u2019s growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company’s shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris L\u00f6w-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board. Iris L\u00f6w-Friedrich … Continue reading \"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-15T20:19:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026","datePublished":"2026-05-15T20:19:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/"},"wordCount":741,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/","name":"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==","datePublished":"2026-05-15T20:19:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE4MjI1MiM0MDIzOTMxNjAjMjAwMDk4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963720"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963720\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}